NEW YORK (360Dx) – Akers Biosciences announced today that it has signed a three-year agreement with the Greater New York Hospital Association — a trade and group purchasing association representing hospitals and healthcare systems in New York, New Jersey, Connecticut, and Rhode Island.

As part of the agreement, Akers Biosciences will market its rapid tests for heparin-induced thrombocytopenia to the association’s 300 hospitals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.